US23416A
(en)
*
|
|
1859-03-29 |
|
Sausage-stxjffer |
US4014335A
(en)
|
1975-04-21 |
1977-03-29 |
Alza Corporation |
Ocular drug delivery device
|
US4300557A
(en)
|
1980-01-07 |
1981-11-17 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method for treating intraocular malignancies
|
US4650764A
(en)
|
1983-04-12 |
1987-03-17 |
Wisconsin Alumni Research Foundation |
Helper cell
|
GB8424757D0
(en)
|
1984-10-01 |
1984-11-07 |
Pasteur Institut |
Retroviral vector
|
FR2573436B1
(fr)
|
1984-11-20 |
1989-02-17 |
Pasteur Institut |
Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
|
US4797368A
(en)
|
1985-03-15 |
1989-01-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adeno-associated virus as eukaryotic expression vector
|
US5139941A
(en)
|
1985-10-31 |
1992-08-18 |
University Of Florida Research Foundation, Inc. |
AAV transduction vectors
|
US4861719A
(en)
|
1986-04-25 |
1989-08-29 |
Fred Hutchinson Cancer Research Center |
DNA constructs for retrovirus packaging cell lines
|
US5643758A
(en)
|
1987-03-10 |
1997-07-01 |
New England Biolabs, Inc. |
Production and purification of a protein fused to a binding protein
|
US4980289A
(en)
|
1987-04-27 |
1990-12-25 |
Wisconsin Alumni Research Foundation |
Promoter deficient retroviral vector
|
US4997652A
(en)
|
1987-12-22 |
1991-03-05 |
Visionex |
Biodegradable ocular implants
|
AU3069189A
(en)
|
1988-02-05 |
1989-08-25 |
Trustees Of Columbia University In The City Of New York, The |
Retroviral packaging cell lines and processes of using same
|
WO1990002806A1
(en)
|
1988-09-01 |
1990-03-22 |
Whitehead Institute For Biomedical Research |
Recombinant retroviruses with amphotropic and ecotropic host ranges
|
US5124263A
(en)
|
1989-01-12 |
1992-06-23 |
Wisconsin Alumni Research Foundation |
Recombination resistant retroviral helper cell and products produced thereby
|
ATE92107T1
(de)
|
1989-04-29 |
1993-08-15 |
Delta Biotechnology Ltd |
N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
|
US5399346A
(en)
|
1989-06-14 |
1995-03-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Gene therapy
|
FR2650598B1
(fr)
|
1989-08-03 |
1994-06-03 |
Rhone Poulenc Sante |
Derives de l'albumine a fonction therapeutique
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
US5164188A
(en)
|
1989-11-22 |
1992-11-17 |
Visionex, Inc. |
Biodegradable ocular implants
|
CA2039921A1
(en)
|
1990-04-16 |
1991-10-17 |
Xandra O. Breakefield |
Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
|
US5264618A
(en)
|
1990-04-19 |
1993-11-23 |
Vical, Inc. |
Cationic lipids for intracellular delivery of biologically active molecules
|
WO1991018088A1
(en)
|
1990-05-23 |
1991-11-28 |
The United States Of America, Represented By The Secretary, United States Department Of Commerce |
Adeno-associated virus (aav)-based eucaryotic vectors
|
EP0550553B1
(en)
|
1990-09-25 |
2000-07-12 |
Cantab Pharmaceuticals Research Limited |
Viral defective vaccine produced by transcomplementing cell line
|
US5173414A
(en)
|
1990-10-30 |
1992-12-22 |
Applied Immune Sciences, Inc. |
Production of recombinant adeno-associated virus vectors
|
US5378475A
(en)
|
1991-02-21 |
1995-01-03 |
University Of Kentucky Research Foundation |
Sustained release drug delivery devices
|
US5252479A
(en)
|
1991-11-08 |
1993-10-12 |
Research Corporation Technologies, Inc. |
Safe vector for gene therapy
|
FR2686901A1
(fr)
|
1992-01-31 |
1993-08-06 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
|
FR2686899B1
(fr)
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
DE656950T1
(de)
*
|
1992-08-21 |
1996-03-14 |
Biogen Inc |
Tat-derivate transport polypeptide.
|
JPH08503855A
(ja)
|
1992-12-03 |
1996-04-30 |
ジェンザイム・コーポレイション |
嚢胞性線維症に対する遺伝子治療
|
US5707643A
(en)
|
1993-02-26 |
1998-01-13 |
Santen Pharmaceutical Co., Ltd. |
Biodegradable scleral plug
|
AU696336B2
(en)
|
1993-03-19 |
1998-09-10 |
Cantab Pharmaceuticals Research Limited |
Defective mutant non-retroviral virus (e.g. HSV) as vaccine
|
FR2705361B1
(fr)
|
1993-05-18 |
1995-08-04 |
Centre Nat Rech Scient |
Vecteurs viraux et utilisation en thérapie génique.
|
FR2705686B1
(fr)
|
1993-05-28 |
1995-08-18 |
Transgene Sa |
Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
|
WO1995002697A1
(fr)
|
1993-07-13 |
1995-01-26 |
Rhone-Poulenc Rorer S.A. |
Vecteurs adenoviraux defectifs et utilisation en therapie genique
|
US5443505A
(en)
|
1993-11-15 |
1995-08-22 |
Oculex Pharmaceuticals, Inc. |
Biocompatible ocular implants
|
FR2714830B1
(fr)
|
1994-01-10 |
1996-03-22 |
Rhone Poulenc Rorer Sa |
Composition contenant des acides nucléiques, préparation et utilisations.
|
FR2716459B1
(fr)
|
1994-02-22 |
1996-05-10 |
Univ Paris Curie |
Système hôte-vecteur utilisable en thérapie génique.
|
US5773021A
(en)
|
1994-03-14 |
1998-06-30 |
Vetoquinol S.A. |
Bioadhesive ophthalmic insert
|
WO1995026411A2
(en)
|
1994-03-25 |
1995-10-05 |
The Uab Research Foundation |
Composition and methods for creating syngeneic recombinant virus-producing cells
|
US5466233A
(en)
|
1994-04-25 |
1995-11-14 |
Escalon Ophthalmics, Inc. |
Tack for intraocular drug delivery and method for inserting and removing same
|
FR2727679B1
(fr)
|
1994-12-05 |
1997-01-03 |
Rhone Poulenc Rorer Sa |
Nouveaux agents de transfection et leurs applications pharmaceutiques
|
US5725493A
(en)
|
1994-12-12 |
1998-03-10 |
Avery; Robert Logan |
Intravitreal medicine delivery
|
IL116816A
(en)
|
1995-01-20 |
2003-05-29 |
Rhone Poulenc Rorer Sa |
Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
|
US5718922A
(en)
|
1995-05-31 |
1998-02-17 |
Schepens Eye Research Institute, Inc. |
Intravitreal microsphere drug delivery and method of preparation
|
US5869079A
(en)
|
1995-06-02 |
1999-02-09 |
Oculex Pharmaceuticals, Inc. |
Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
|
AU6043396A
(en)
|
1995-06-05 |
1996-12-24 |
University Of Alabama At Birmingham Research Foundation, The |
Composition and methods for creating syngeneic recombinant v irus-producing cells
|
US5773019A
(en)
|
1995-09-27 |
1998-06-30 |
The University Of Kentucky Research Foundation |
Implantable controlled release device to deliver drugs directly to an internal portion of the body
|
FR2741358B1
(fr)
|
1995-11-17 |
1998-01-02 |
Centre Nat Rech Scient |
Production de vecteurs retroviraux par l'intermediaire de vecteurs viraux a base de virus a adn
|
US5902598A
(en)
|
1997-08-28 |
1999-05-11 |
Control Delivery Systems, Inc. |
Sustained release drug delivery devices
|
FR2773320B1
(fr)
|
1998-01-05 |
2000-03-03 |
Optisinvest |
Dispositif pour le transfert intraoculaire de produits actifs par iontophorese
|
US6869775B2
(en)
*
|
1998-02-06 |
2005-03-22 |
Millennium Pharmaceuticals, Inc. |
Card related protein and uses thereof
|
US6482933B1
(en)
*
|
1998-02-06 |
2002-11-19 |
Millennium Pharmaceuticals, Inc. |
Molecules of the card-related protein family and uses thereof
|
AU5819599A
(en)
|
1998-09-11 |
2000-04-03 |
Regents Of The University Of California, The |
Recombinant adenovirus for tissue specific expression in heart
|
US6410045B1
(en)
|
1999-02-22 |
2002-06-25 |
Clyde Lewis Schultz |
Drug delivery system for antiglaucomatous medication
|
ATE363465T1
(de)
*
|
1999-04-09 |
2007-06-15 |
Cytovia Inc |
Caspase inhibitoren und ihre verwendung
|
US6953657B2
(en)
*
|
1999-06-28 |
2005-10-11 |
Millennium Pharmaceuticals, Inc. |
Molecules of the CARD-related protein family and uses thereof
|
US6756196B2
(en)
*
|
1999-06-28 |
2004-06-29 |
Millennium Pharmaceuticals, Inc. |
Molecules of the card-related protein family and uses thereof
|
US6331313B1
(en)
|
1999-10-22 |
2001-12-18 |
Oculex Pharmaceticals, Inc. |
Controlled-release biocompatible ocular drug delivery implant devices and methods
|
US6821775B1
(en)
|
2000-02-11 |
2004-11-23 |
Genvec, Inc. |
Viral vector encoding pigment epithelium-derived factor
|
CA2747325A1
(en)
|
2000-04-12 |
2001-10-25 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US6375972B1
(en)
|
2000-04-26 |
2002-04-23 |
Control Delivery Systems, Inc. |
Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
|
US6833248B2
(en)
*
|
2000-05-09 |
2004-12-21 |
Pharmacia & Upjohn Company |
Human caspase-12 materials and methods
|
US6726918B1
(en)
|
2000-07-05 |
2004-04-27 |
Oculex Pharmaceuticals, Inc. |
Methods for treating inflammation-mediated conditions of the eye
|
AU2001296333A1
(en)
|
2000-09-26 |
2002-04-08 |
The Burnham Institute |
Paad domain-containing polypeptides, encoding nucleic acids, and methods of use
|
US20050142130A1
(en)
|
2001-01-04 |
2005-06-30 |
Roks Antonius J.M. |
Use of angiotensin-(1-7) for preventing and/or reducing the formation of neointima
|
US6713081B2
(en)
|
2001-03-15 |
2004-03-30 |
The United States Of America As Represented By The Department Of Health And Human Services |
Ocular therapeutic agent delivery devices and methods for making and using such devices
|
WO2003078648A2
(en)
|
2002-03-11 |
2003-09-25 |
Curagen Corporation |
Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
|
WO2003087128A2
(en)
|
2002-04-09 |
2003-10-23 |
Rmf Dictagene S.A. |
Secretory signal sequences and uses thereof
|
US7071172B2
(en)
|
2002-04-30 |
2006-07-04 |
The University Of North Carolina At Chapel Hill |
Secretion signal vectors
|
CN1241946C
(zh)
|
2002-07-01 |
2006-02-15 |
美国福源集团 |
对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
|
KR100472938B1
(ko)
|
2002-10-31 |
2005-03-11 |
학교법인 한림대학교 |
세포침투 효율을 향상시킨 수송도메인-목표단백질-수송도메인 융합단백질 및 그 용도
|
US20050129685A1
(en)
|
2003-09-18 |
2005-06-16 |
Jingtai Cao |
Use of IL-1 blockers to prevent corneal inflammation and neovascularization
|
JP2008538285A
(ja)
|
2005-04-07 |
2008-10-23 |
ユニバーシティ・オブ・サウス・フロリダ |
POP2NFkB阻害ポリペプチド、核酸および使用方法
|
CN101595228A
(zh)
|
2005-07-21 |
2009-12-02 |
艾博特公司 |
包括sorf构建体的多基因表达和使用多蛋白、前体蛋白和蛋白酶解的方法
|
US20090148894A1
(en)
|
2005-08-15 |
2009-06-11 |
Broedel Sheldon E |
Methods for optimizing the secretion of protein in prokaryotes
|
EP1873251A1
(en)
|
2006-06-29 |
2008-01-02 |
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus |
Expression vector(s) for enhanced expression of a protein of interest in eukaryotic or prokaryotic host cells
|
WO2008057434A2
(en)
|
2006-11-06 |
2008-05-15 |
Merck & Co., Inc. |
Method for identifying modulators of the nrf2-keap1-are pathway
|
EP2134173A4
(en)
|
2007-03-01 |
2010-11-10 |
Wellstat Ophthalmics Corp |
TREATMENT OF DISEASES SIGNED BY IGNITION
|
US9725485B2
(en)
|
2012-05-15 |
2017-08-08 |
University Of Florida Research Foundation, Inc. |
AAV vectors with high transduction efficiency and uses thereof for gene therapy
|
JP5552048B2
(ja)
*
|
2007-06-21 |
2014-07-16 |
ムスク ファンデーション フォー リサーチ ディベロップメント |
加齢性黄斑変性を治療するためのアルファコネキシンc末端(act)ペプチド
|
CA2727971A1
(en)
|
2007-08-29 |
2009-03-12 |
Tufts University |
Methods of making and using a cell penetrating peptide for enhanced delivery of nucleic acids, proteins, drugs, and adenovirus to tissues and cells, and compositions and kits
|
JP5635912B2
(ja)
|
2008-01-15 |
2014-12-03 |
アッヴィ・インコーポレイテッド |
改善された哺乳動物発現ベクター及びその使用
|
US20120108654A1
(en)
*
|
2008-06-30 |
2012-05-03 |
The Johns Hopkins University |
Compositions and methods for the treatment of ocular oxidative stress and retinitis pigmentosa
|
US11512326B2
(en)
|
2009-05-26 |
2022-11-29 |
University Of Florida Research Foundation, Incorporated |
Small angiotensin peptide expression system in mammalian cells
|
EP2295072A1
(en)
|
2009-09-15 |
2011-03-16 |
Max-Delbrück-Centrum für Molekulare Medizin (MDC) |
Use of ARC for inhibiting cell death during liver failure
|
KR101214362B1
(ko)
|
2011-02-15 |
2012-12-21 |
한림대학교 산학협력단 |
Fk506 결합 단백질 융합 단백질을 함유하는 안과 질환 예방 및 치료용 점안제 조성물
|
CN103889461B
(zh)
|
2011-07-18 |
2016-11-09 |
肯塔基大学研究基金会 |
保护细胞免于alu-rna诱导的变性和用于保护细胞的抑制剂
|
WO2013067036A1
(en)
|
2011-10-31 |
2013-05-10 |
Rutgers, The State University Of New Jersey |
Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators
|
WO2013090318A1
(en)
|
2011-12-12 |
2013-06-20 |
Trustees Of Boston University |
Utility of insulin-like 6 (insl6) for the treatment of autoimmune diseases
|
CA2877384C
(en)
|
2012-07-02 |
2023-05-09 |
Iprogen Biotech Inc. |
Intracellular protein delivery
|
EP2919816B1
(en)
|
2012-11-14 |
2019-03-27 |
Daniel Offen |
Combination treatment for amyotrophic lateral sclerosis (als)
|
US10981961B2
(en)
|
2013-03-11 |
2021-04-20 |
University Of Florida Research Foundation, Incorporated |
Delivery of card protein as therapy for occular inflammation
|
WO2015127094A1
(en)
|
2014-02-19 |
2015-08-27 |
University Of Florida Research Foundation, Inc. |
Delivery of nrf2 as therapy for protection against reactive oxygen species
|
AU2015229381B2
(en)
|
2014-03-11 |
2019-11-07 |
University Of Florida Research Foundation, Inc. |
Use of AAV-expressed M013 protein as an anti-inflammatory therapeutic
|